Logo image of ENTA

ENANTA PHARMACEUTICALS INC (ENTA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ENTA - US29251M1062 - Common Stock

12.57 USD
+0.08 (+0.64%)
Last: 1/21/2026, 8:13:23 PM
12.57 USD
0 (0%)
After Hours: 1/21/2026, 8:13:23 PM
Fundamental Rating

2

Overall ENTA gets a fundamental rating of 2 out of 10. We evaluated ENTA against 525 industry peers in the Biotechnology industry. ENTA may be in some trouble as it scores bad on both profitability and health. ENTA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ENTA had negative earnings in the past year.
  • ENTA had a negative operating cash flow in the past year.
  • ENTA had negative earnings in each of the past 5 years.
  • ENTA had a negative operating cash flow in each of the past 5 years.
ENTA Yearly Net Income VS EBIT VS OCF VS FCFENTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -29.17%, ENTA is in the better half of the industry, outperforming 67.81% of the companies in the same industry.
  • The Return On Equity of ENTA (-126.53%) is worse than 60.95% of its industry peers.
Industry RankSector Rank
ROA -29.17%
ROE -126.53%
ROIC N/A
ROA(3y)-29.64%
ROA(5y)-27.87%
ROE(3y)-92.79%
ROE(5y)-67.21%
ROIC(3y)N/A
ROIC(5y)N/A
ENTA Yearly ROA, ROE, ROICENTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • ENTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTA Yearly Profit, Operating, Gross MarginsENTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

  • ENTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ENTA has been increased compared to 1 year ago.
  • Compared to 5 years ago, ENTA has more shares outstanding
  • The debt/assets ratio for ENTA is higher compared to a year ago.
ENTA Yearly Shares OutstandingENTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
ENTA Yearly Total Debt VS Total AssetsENTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • ENTA has an Altman-Z score of -1.12. This is a bad value and indicates that ENTA is not financially healthy and even has some risk of bankruptcy.
  • ENTA has a Altman-Z score (-1.12) which is in line with its industry peers.
  • A Debt/Equity ratio of 1.74 is on the high side and indicates that ENTA has dependencies on debt financing.
  • ENTA has a worse Debt to Equity ratio (1.74) than 77.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.74
Debt/FCF N/A
Altman-Z -1.12
ROIC/WACCN/A
WACC8.53%
ENTA Yearly LT Debt VS Equity VS FCFENTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • ENTA has a Current Ratio of 4.21. This indicates that ENTA is financially healthy and has no problem in meeting its short term obligations.
  • ENTA has a Current ratio of 4.21. This is comparable to the rest of the industry: ENTA outperforms 50.29% of its industry peers.
  • ENTA has a Quick Ratio of 4.21. This indicates that ENTA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.21, ENTA is in line with its industry, outperforming 51.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.21
Quick Ratio 4.21
ENTA Yearly Current Assets VS Current LiabilitesENTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 30.11% over the past year.
  • Looking at the last year, ENTA shows a decrease in Revenue. The Revenue has decreased by -3.42% in the last year.
  • ENTA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.82% yearly.
EPS 1Y (TTM)30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.03%
Revenue 1Y (TTM)-3.42%
Revenue growth 3Y-8.83%
Revenue growth 5Y-11.82%
Sales Q2Q%3.55%

3.2 Future

  • Based on estimates for the next years, ENTA will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.36% on average per year.
  • Based on estimates for the next years, ENTA will show a quite strong growth in Revenue. The Revenue will grow by 18.57% on average per year.
EPS Next Y18.3%
EPS Next 2Y15.48%
EPS Next 3Y11.77%
EPS Next 5Y12.36%
Revenue Next Year-2.24%
Revenue Next 2Y-1.03%
Revenue Next 3Y1.08%
Revenue Next 5Y18.57%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ENTA Yearly Revenue VS EstimatesENTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
ENTA Yearly EPS VS EstimatesENTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ENTA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTA Price Earnings VS Forward Price EarningsENTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTA Per share dataENTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.48%
EPS Next 3Y11.77%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ENTA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ENANTA PHARMACEUTICALS INC

NASDAQ:ENTA (1/21/2026, 8:13:23 PM)

After market: 12.57 0 (0%)

12.57

+0.08 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17
Earnings (Next)02-09
Inst Owners71.24%
Inst Owner Change-0.05%
Ins Owners4.67%
Ins Owner Change-0.35%
Market Cap362.77M
Revenue(TTM)65.32M
Net Income(TTM)-81.89M
Analysts82.86
Price Target19.51 (55.21%)
Short Float %7.58%
Short Ratio6.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.59%
Min EPS beat(2)16.46%
Max EPS beat(2)34.72%
EPS beat(4)4
Avg EPS beat(4)20.9%
Min EPS beat(4)8.52%
Max EPS beat(4)34.72%
EPS beat(8)5
Avg EPS beat(8)6.94%
EPS beat(12)9
Avg EPS beat(12)11.89%
EPS beat(16)10
Avg EPS beat(16)6.01%
Revenue beat(2)1
Avg Revenue beat(2)4.24%
Min Revenue beat(2)-7.07%
Max Revenue beat(2)15.55%
Revenue beat(4)1
Avg Revenue beat(4)-0.85%
Min Revenue beat(4)-8.27%
Max Revenue beat(4)15.55%
Revenue beat(8)3
Avg Revenue beat(8)-4.27%
Revenue beat(12)6
Avg Revenue beat(12)-2.67%
Revenue beat(16)6
Avg Revenue beat(16)-4.05%
PT rev (1m)0.66%
PT rev (3m)9.73%
EPS NQ rev (1m)-3.86%
EPS NQ rev (3m)20.83%
EPS NY rev (1m)-0.89%
EPS NY rev (3m)5.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.55
P/FCF N/A
P/OCF N/A
P/B 5.61
P/tB 5.61
EV/EBITDA N/A
EPS(TTM)-3.83
EYN/A
EPS(NY)-3.13
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS2.26
BVpS2.24
TBVpS2.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.17%
ROE -126.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.64%
ROA(5y)-27.87%
ROE(3y)-92.79%
ROE(5y)-67.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 1.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 281.2%
Cap/Sales 19.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.21
Quick Ratio 4.21
Altman-Z -1.12
F-Score4
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)477.27%
Cap/Depr(5y)305.21%
Cap/Sales(3y)19.24%
Cap/Sales(5y)12.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.03%
EPS Next Y18.3%
EPS Next 2Y15.48%
EPS Next 3Y11.77%
EPS Next 5Y12.36%
Revenue 1Y (TTM)-3.42%
Revenue growth 3Y-8.83%
Revenue growth 5Y-11.82%
Sales Q2Q%3.55%
Revenue Next Year-2.24%
Revenue Next 2Y-1.03%
Revenue Next 3Y1.08%
Revenue Next 5Y18.57%
EBIT growth 1Y29.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.21%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y66.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.53%
OCF growth 3YN/A
OCF growth 5YN/A

ENANTA PHARMACEUTICALS INC / ENTA FAQ

What is the fundamental rating for ENTA stock?

ChartMill assigns a fundamental rating of 2 / 10 to ENTA.


Can you provide the valuation status for ENANTA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ENANTA PHARMACEUTICALS INC (ENTA). This can be considered as Overvalued.


Can you provide the profitability details for ENANTA PHARMACEUTICALS INC?

ENANTA PHARMACEUTICALS INC (ENTA) has a profitability rating of 1 / 10.